Total
0
Shares
Invion (ASX:IVX) - Executive Chair & CEO, Thian Chew
Executive Chair & CEO, Thian Chew
Source: Thian Chew / LinkedIn
Market Herald logo

Find out more about this capital raise

Be the first with the news that moves the market
  • Invion (IVX) ends the week in a trading halt while it plans the details of an upcoming capital raising
  • The company will remain in the halt until November 16 or when more details are released, whichever occurs first
  • On October 28, Invion released trial results which showed a complete regression in mice with breast cancer when taking its INV043 drug
  • Results from the study showed a complete regression in the tumour and appeared to trigger an immune response that prevents the recurrence of the cancer
  • Shares in Invion last traded at 2.7 cents on November 11

Invion (IVX) has ended the week in a trading halt while it plans the details of an upcoming capital raising.

The company will remain in the halt until November 16 or when more details are released, whichever occurs first.

Invion is yet to disclose how much it intends to raise or what it will use the funds for once received.

On October 28, Invion released trial results which showed a complete regression in tumours following in vivo treatment.

These findings come from the company’s recent trial which used its INV043 drug to treat immunocompetent mice that were implanted with triple-negative breast cancer (TNBC).

Results from the study showed a complete regression in the tumour and appeared to trigger an immune response that prevents the recurrence of TNBC.

Additionally, none of the mice experienced scarring or tumour spread.

Invion last undertook a capital raising in June 2021 when it received $4.5 million under a partnership with RMW Cho Group.

Both companies entered an agreement to co-develop Photosoft technology in the treatment of atherosclerosis and infectious diseases.

Invion did not pocket all the funds as it paid RMW a one-time fee of $2.25 million to co-develop the tech.

Shares in Invion last traded at 2.7 cents on November 11. The company has a $158.3 million market cap.

IVX by the numbers
More From The Market Herald
Kopore Metals (ASX:KMT) - Managing Director, Simon Jackson (right)

" Kopore Metals (ASX:KMT) planning capital raise

Kopore Metals (KMT) has entered into a trading halt ahead of an upcoming capital raise.
Bio Gene Technology (ASX:BGT) - CEO & Managing Director, Richard Jagger

" Bio-Gene Technology (ASX:BGT) halts trade following research agreement

Bio-Gene Technology (BGT) has placed its shares in a trading halt while it plans the details of an upcoming capital raising.
Johns Lyng Group (ASX:JLG) - Managing Director and CEO, Scott Didier

" Johns Lyng Group (ASX:JLG) in back-to-back trading halts

Johns Lyng Group (JLG) has entered consecutive trading halts regarding a ‘material’ transaction and a capital raise.
Environmental Group (ASX:EGL) - Chairwoman, Lynn Richardson

" Environmental Group (ASX:EGL) pauses trading as it plans capital raise

The Environmental Group (EGL) has entered into a trading halt as it plans an upcoming capital raise.